{"text": "jounce doubled its cash holdings with a 120m upfront commitment from gilead in a deal for a preclinical anti ccr8 program affording the smaller biotech greater runway ahead of upcoming trial starts and clinical readouts jnce gild"}
{"text": "jnce jounce will lead development of jtx 1811 through ind clearance and thereafter gilead will have the sole right to develop jtx 1811 gild"}
{"text": "gild agreed with jounce jnce a clinical stage company focused on cancer immunotherapies and predictive biomarkers to exclusively license its jtx 1811 immunotherapy program jnce 7 53 usd 2 69 55 58 jnce will get 35m in equity 685m milestones"}
{"text": "attention biotech investors mark your calendar for september pdufa dates gild bmrn bmy mnk bhc"}
{"text": "cocp extremely secretive cocrystal aggresively negotiating covid 19 mkt partner most likely turned down an offer use jnce as an example of a low ball offer which why a quick cash raise now with 40m cash zero debt cc gild regn"}
{"text": "jnce jounce getting 120 mil basically from gild worth more than 7 69 sh now for sure well see"}
